Herpes simplex vaccine - Agenus
Alternative Names: AG-707; HerpV; rhHSP70-PCLatest Information Update: 02 Oct 2021
At a glance
- Originator Antigenics
- Developer Agenus
- Class Viral vaccines
- Mechanism of Action CD4-positive T-lymphocyte stimulants; CD8 positive T lymphocyte stimulants; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Herpes simplex virus infections
Highest Development Phases
- Discontinued Herpes simplex virus type 2 infections
Most Recent Events
- 16 Mar 2015 Agenus has patent protection for HerpV vaccine in USA
- 01 Jan 2015 Agenus completes a phase II trial in Herpes simplex virus infections (recurrent, adjunctive therapy) in USA (SC)(NCT01687595)
- 26 Jun 2014 HerpV is available for licensing (\http://www.agenusbio.com/\)